ZYME — Zymeworks Inc. Common Stock

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Zymeworks Inc. Common Stock

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to th… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$24.79
Market Cap$1.85B
Float68.1M
Shares Outstanding73.0M
P/E (Forward)25.13
Price/Sales (TTM)22.73
vs. Analyst Target+62.0% to analyst PT
Profit Margin-126.33%
Operating Margin (TTM)-1956.73%
Revenue (TTM)$81.3M
Dividend RateNone
Analyst Target Price$40.15 (10 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $39.0M -$181M $39.0M -$177M
2021 $26.7M -$212M $26.7M -$206M
2022 $412M $124M $412M $143M
2023 $76.0M -$119M -$67.0M -$121M
2024 $76.3M -$123M $76.3M -$109M
2025 $106M -$81.1M $106M -$81.4M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $48.7M $2.3M
Sep 2025 $27.6M -$19.6M
Dec 2025 $2.5M -$41.2M
Mar 2026 $2.4M -$44.2M

Ownership & Float

Insider Ownership1.3%
Institutional Ownership99.0%
Short Float6.8%
% of All Funds Holding2.37%
Number of Funds Holding195

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$25.70Near-term / short-term trend
Weekly40-Week SMA$22.46Medium-term trend
Weekly80-Week SMA$17.78Cyclical trend (business cycle)
Weekly200-Week SMA$12.51Secular trend (multi-year)
Monthly10-Month SMA$22.72Near-term monthly trend
Monthly20-Month SMA$17.95Medium-term monthly trend
Monthly40-Month SMA$13.57Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$22.60 support 1.05x 1 months ago
$19.00 support 2.55x 5 months ago
$17.00 support 1.68x 6 months ago
$14.00 support 1.12x 7 months ago
$10.50 support 1.45x 20 months ago

Historical Earnings Reactions (37 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.63% -0.82% 40.54% 11.76% -9.79%
1 Day -0.67% -1.04% 40.54% 12.79% -10.19%
1 Week 0.07% 0.46% 54.05% 21.39% -25.89%
2 Weeks 1.42% 1.94% 54.05% 34.19% -33.28%
1 Month 4.92% 3.65% 61.11% 44.53% -29.65%

Next earnings: July 26, 2026 (59 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan1.6%44.4%9
Feb-5.7%33.3%9
Mar-2.1%44.4%9
Apr4.6%66.7%9
May1.8%33.3%9
Jun-4.6%55.6%9
Jul-3.1%44.4%9
Aug10.4%88.9%9
Sep3.9%44.4%9
Oct4.3%66.7%9
Nov13.5%77.8%9
Dec0.5%55.6%9

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.09% 50.4% 427
Tuesday 0.08% 48.7% 470
Wednesday 0.10% 50.4% 466
Thursday -0.18% 50.0% 458
Friday 0.43% 50.3% 459

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 99.0%

Insider Transactions — Smart Summary

Total insider ownership: 1.3%

Founder-led management: Ali Tehrani (President & Chief Executive Officer)

12-Month Insider Activity Summary

Total Filings8
Net Value-$4.7M
Net Shares Change200,567
% of Float0.3%
C-Suite Filings8
Clusters Detected2

Key Insiders

NameTitleNet ValueFilingsActivity
Galbraith Kenneth Chair and CEO -$3.3M 3 N/A
Moore Paul Andrew Chief Scientific Officer -$721,457.319 2 N/A
Smith Jeffrey T L EVP and Chief Medical Officer -$475,561.417 2 N/A
Hollywood Mark EVP and Chief Operating Officer -$138,761.82 1 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-12-22 – 2026-01-05 4 3 -$3.4M 4 C-suite
2026-01-12 – 2026-01-13 4 4 -$1.3M 4 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-01-05 Galbraith Kenneth Chair and CEO -$1.4M Transaction at $25.10, now -1.2%
2025-12-22 Galbraith Kenneth Chair and CEO -$1.3M Transaction at $27.02, now -8.3%
2026-01-12 Smith Jeffrey T L EVP and Chief Medical Officer -$211,090.285 Transaction at $22.67, now +9.3%
2026-01-12 Moore Paul Andrew Chief Scientific Officer -$216,758.66 Transaction at $22.67, now +9.3%
2026-01-12 Galbraith Kenneth Chair and CEO -$689,818.564 Transaction at $22.67, now +9.3%
2026-01-05 Smith Jeffrey T L EVP and Chief Medical Officer -$264,471.132 Transaction at $25.10, now -1.2%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Zymeworks Inc. Common Stock (ZYME) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for ZYME on Trend Edge →